Subscribe
360b-shutterstock-com-9
360b / Shutterstock.com
22 July 2015Americas

Federal Circuit says ‘patent dance’ is optional

The US Court of Appeals for the Federal Circuit has ruled that biosimilar applicants can opt out of the so-called patent dance, paving the way for Sandoz to sell a biosimilar version of an Amgen drug.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
Sandoz appeals to US Supreme Court over ‘patent dance’ ruling
17 February 2016   Sandoz has petitioned the US Supreme Court to review the US Court of Appeals for the Federal Circuit’s ruling in the ‘patent dance’ dispute.
Americas
Federal Circuit denies rehearing in ‘patent dance’ case
19 October 2015   The US Court of Appeals for the Federal Circuit has declined to hear the Amgen v Sandoz ‘patent dance’ dispute en banc.
Americas
Sandoz launches Zarxio biosimilar
4 September 2015   Drug maker Sandoz has officially launched its Zarxio biosimilar after a US appeals court declined to issue an injunction that would have prevented it from being sold.


Editor's picks

Life sciences leaders recognised at LSPN Awards USA 2025
Americas
Life sciences leaders recognised at LSPN Awards USA 2025
8 May 2025

Editor's picks

Americas
Life sciences leaders recognised at LSPN Awards USA 2025
8 May 2025
Americas
LSPN: Using ‘the patentee’s friend’ in Section 112 claims
6 May 2025
Americas
Why US patent reform is ‘essential’ for US economic prosperity and security
29 April 2025
Europe
Meril v Edwards: Harmonisation of obviousness at the UPC and the EPO
24 April 2025
Americas
WIPR Diversity & Inclusion reveals Top 100 People in IP for 2025
24 April 2025
Big Pharma
AstraZeneca unit faces class-action suit over alleged Soliris monopoly
17 April 2025

More on this story

Americas
Sandoz appeals to US Supreme Court over ‘patent dance’ ruling
17 February 2016   Sandoz has petitioned the US Supreme Court to review the US Court of Appeals for the Federal Circuit’s ruling in the ‘patent dance’ dispute.
Americas
Federal Circuit denies rehearing in ‘patent dance’ case
19 October 2015   The US Court of Appeals for the Federal Circuit has declined to hear the Amgen v Sandoz ‘patent dance’ dispute en banc.
Americas
Sandoz launches Zarxio biosimilar
4 September 2015   Drug maker Sandoz has officially launched its Zarxio biosimilar after a US appeals court declined to issue an injunction that would have prevented it from being sold.

More on this story

Americas
Sandoz appeals to US Supreme Court over ‘patent dance’ ruling
17 February 2016   Sandoz has petitioned the US Supreme Court to review the US Court of Appeals for the Federal Circuit’s ruling in the ‘patent dance’ dispute.
Americas
Federal Circuit denies rehearing in ‘patent dance’ case
19 October 2015   The US Court of Appeals for the Federal Circuit has declined to hear the Amgen v Sandoz ‘patent dance’ dispute en banc.
Americas
Sandoz launches Zarxio biosimilar
4 September 2015   Drug maker Sandoz has officially launched its Zarxio biosimilar after a US appeals court declined to issue an injunction that would have prevented it from being sold.

More features

Life sciences leaders recognised at LSPN Awards USA 2025
UK-India trade deal is ‘a missed opportunity for UK pharma’, says industry body
LSPN: Counsel grapple with AI’s impact on training and critical thinking
'Nothing can stand in the way of our work': Ukraine resumes IP system
LSPN: Trump's policy storm causing chaos and confusion
Taylor Wessing expands in Europe with Paris team
LSPN: Using ‘the patentee’s friend’ in Section 112 claims
ResMed voids sleep apnoea tech patent at PTAB